Coherus BioSciences (CHRS) Earnings Date, Estimates & Call Transcripts $1.02 -0.11 (-9.73%) (As of 09/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 4EstimatedActual EPS (Aug. 8) -$0.20 Beat By $0.10 Consensus EPS (Aug. 8) -$0.30 Get Coherus BioSciences Earnings AlertsEnter your email address below to receive the latest news and earnings results for CHRS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCHRS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CHRS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?Click here to uncover how you can get in on the ground floor. Coherus BioSciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ4 20241($0.25)($0.25)($0.25) CHRS Earnings Date and InformationCoherus BioSciences last issued its earnings data on August 8th, 2024. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million for the quarter, compared to analysts' expectations of $57.08 million. Coherus BioSciences has generated ($0.78) earnings per share over the last year (($0.78) diluted earnings per share). Earnings for Coherus BioSciences are expected to grow in the coming year, from ($1.07) to ($0.85) per share. Coherus BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off prior year's report dates.Read More Coherus BioSciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/4/2024(Estimated)------- 8/8/2024Q2 2024($0.30)($0.20)+$0.10($0.29)$57.08 million$64.98 million5/9/2024Q1 2024($0.05)($0.38)($0.33)($1.59)$102.00 million$77.06 million 3/13/2024Q4 2023($0.33)($0.72)($0.39)($0.73)$105.30 million$91.52 million 11/6/2023Q3 2023($0.45)($0.38)+$0.07($0.35)$80.13 million$74.57 million 8/2/2023Q2 2023($0.66)($0.49)+$0.17($0.49)$50.83 million$58.72 million 5/8/2023Q1 2023($0.77)($0.89)($0.12)($0.82)$50.73 million$32.44 million Get the Latest News and Ratings for CHRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. 3/6/2023Q4 2022($0.64)($0.76)($0.12)($0.76)$45.72 million$45.35 million 11/8/2022Q3 2022($0.79)($1.11)($0.32)($1.11)$57.23 million$45.42 million 8/4/2022Q2 2022($0.96)($0.65)+$0.31($0.65)$58.00 million$60.15 million 5/5/2022Q1 2022($0.80)($1.24)($0.44)($1.24)$68.07 million$60.12 million 2/17/2022Q4 2021($0.61)($0.60)+$0.01($0.60)$83.32 million$73.37 million 11/7/2021Q3 2021($0.22)($0.34)($0.12)($0.49)$86.96 million$82.50 million 8/5/2021Q2 2021($0.25)($0.40)($0.15)($0.40)$82.65 million$87.64 million 5/6/2021Q1 2021$0.09($2.37)($2.46)($2.37)$97.87 million$83.03 million 2/23/2021Q4 2020$0.25$0.12($0.13)$0.12$114.90 million$110.42 million 11/5/2020Q3 2020$0.34$0.33($0.01)$0.33$120.50 million$113.55 million 8/6/2020Q2 2020$0.26$0.70+$0.44$0.70$100.33 million$135.67 million 5/7/2020Q1 2020$0.44$0.54+$0.10$0.60$116.25 million$116.18 million 2/27/2020Q4 2019$0.68$0.56($0.12)$0.53$123.60 million$123.86 million 11/6/2019Q3$0.36$0.63+$0.27$0.63$93.58 million$111.68 million Coherus BioSciences Earnings - Frequently Asked Questions When is Coherus BioSciences's earnings date? Coherus BioSciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates. Learn more on CHRS's earnings history. Did Coherus BioSciences beat their earnings estimates last quarter? In the previous quarter, Coherus BioSciences (NASDAQ:CHRS) reported ($0.20) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.30) by $0.10. Learn more on analysts' earnings estimate vs. CHRS's actual earnings. How much revenue does Coherus BioSciences generate each year? Coherus BioSciences (NASDAQ:CHRS) has a recorded annual revenue of $308.13 million. How much profit does Coherus BioSciences generate each year? Coherus BioSciences (NASDAQ:CHRS) has a recorded net income of -$237.89 million. CHRS has generated -$0.78 earnings per share over the last four quarters. What is Coherus BioSciences's EPS forecast for next year? Coherus BioSciences's earnings are expected to grow from ($1.07) per share to ($0.85) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CGEN Earnings BDTX Earnings ALEC Earnings TERN Earnings ELYM Earnings SIGA Earnings APLT Earnings SLN Earnings ARCT Earnings ALT Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:CHRS) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.